Drugs / ILV-095
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01010542 Comparator | Dec 2009 → May 2011 | psoriasis | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00822484 Comparator | Feb → Sep 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00822835 Comparator | Jan → Aug 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ILV-095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00822835 ↗ |
| Route | Subcutaneous | “ILV-095 Administered Subcutaneously to Healthy Japanese Male Subjects” NCT00822484 ↗ |